Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA.

References

• McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011;71(18):2457–2489.
   PubMed Web of Science ®Google Scholar
• Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105–118.
   PubMed Web of Science ®Google Scholar
• Pawlosky N. Cardiovascular risk: are all NSAIDs alike? Can Pharm J (Ott). 2013;146(2):80–83.
   PubMedGoogle Scholar
• Varga Z, Sabzwari SRA, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus. 2017;9(4):e1144.
   PubMed Web of Science ®Google Scholar
• Brophy JM. Celecoxib and cardiovascular risks. Expert Opin Drug Saf. 2005;4(6):1005–1015.
   PubMedGoogle Scholar
• Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99(3):132–140.
   PubMed Web of Science ®Google Scholar
• Horl WH. Nonsteroidal anti-inflammatory drugs and the kidney. Pharmaceuticals (Basel). 2010;3(7):2291–2321.
   PubMedGoogle Scholar
• Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25(7):537–544.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama. 2000;284(10):1247–1255.
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Arroyo MT, et al. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121–132.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Rainsford KD. Are cyclooxygenase 2 inhibitors free of gastrointestinal side effects? West J Med. 2001;175(4):267–268.
   PubMedGoogle Scholar
• Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther. 2005;7(Suppl 4):S14–22.
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7(3):R644–65.
   PubMed Web of Science ®Google Scholar
• Therapeutic Guidelines Limited. Therapeutic guidelines: rheumatology. Version 3. 2017. [cited 2018 Aug 15]. Available from: http://www.tg.org.au/.
   Google Scholar
• Roumie CL, Arbogast PG, Mitchel EF Jr., et al. Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. J Gen Intern Med. 2005;20(10):879–883.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS). 2018. [cited 2018 Aug 15]. Available from: https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/ucm070093.htm.
   Google Scholar
• Health Canada. Canada vigilance adverse reaction online database 2018. [cited 2018 Aug 15]. Available from: http://cvp-pcv.hc-sc.gc.ca/arq-rei/index-eng.jsp.
   Google Scholar
• Australian Therapeutic Goods Administration. Database of adverse event notifications (DAEN). 2018. [cited 2018 Aug 15]. Available from: https://www.tga.gov.au/database-adverse-event-notifications-daen.
   Google Scholar
• McDonald CJ, Kalisch Ellett LM, Barratt JD, et al. An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Pharmacoepidemiol Drug Saf. 2015;24(4):399–405.
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Graham DY, Husni ME, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018;47(11):1453–1463.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529.
   PubMed Web of Science ®Google Scholar
• Australian Medicines Handbook: Australian medicines handbook Pty. Ltd. 2018. [cited 2018 Aug 15]. Available from: http://amhonline.amh.net.au/.
   Google Scholar
• Onuigbo MA, Agbasi N. “Quadruple whammy”- a preventable newly described syndrome of post-operative AKI in CKD II and CKD III patients on combination “Triple whammy” medications: a Mayo Clinic Health System, Eau Claire, Wisconsin experience. Niger J Clin Pract. 2014;17(5):649–654.
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S3.
   PubMed Web of Science ®Google Scholar
• Lanas A. A review of the gastrointestinal safety data–a gastroenterologist’s perspective. Rheumatology (Oxford). 2010;49(Suppl 2):ii3–10.
   PubMed Web of Science ®Google Scholar
• Nagata N, Niikura R, Aoki T, et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest Endosc. 2014;80(6):1124–1131.
   PubMed Web of Science ®Google Scholar
• Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29(5):481–496.
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–162.
   PubMed Web of Science ®Google Scholar
• Clinard F, Sgro C, Bardou M, et al. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol. 2004;60(4):279–283.
   PubMed Web of Science ®Google Scholar
• Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev. 2008;88(4):1547–1565.
   PubMed Web of Science ®Google Scholar
• Thomas MC. Diuretics, ACE inhibitors and NSAIDs–the triple whammy. Med J Aust. 2000;172(4):184–185.
   PubMed Web of Science ®Google Scholar
• Loboz KK, Shenfield GM. Drug combinations and impaired renal function – the ‘triple whammy’. Br J Clin Pharmacol. 2005;59(2):239–243.
   PubMed Web of Science ®Google Scholar
• Camin RM, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: “The Triple Whammy”. Nefrologia. 2015;35(2):197–206.
   PubMed Web of Science ®Google Scholar
• Prieto-Garcia L, Pericacho M, Sancho-Martinez SM, et al. Mechanisms of triple whammy acute kidney injury. Pharmacol Ther. 2016;167:132–145.
   PubMed Web of Science ®Google Scholar
• Howes LG. Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Ther Clin Risk Manag. 2007;3(5):831–845.
   PubMedGoogle Scholar
• Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061–1075.
   PubMed Web of Science ®Google Scholar
• Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490–496.
   PubMed Web of Science ®Google Scholar